Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94


Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation.

Bonnefond ML, Florent R, Lenoir S, Lambert B, Abeilard E, Giffard F, Louis MH, Elie N, Briand M, Vivien D, Poulain L, Gauduchon P, N'Diaye M.

Oncotarget. 2018 Sep 21;9(74):33896-33911. doi: 10.18632/oncotarget.26084. eCollection 2018 Sep 21.


The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.

Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.

Mol Cancer Ther. 2017 Jan;16(1):102-115. doi: 10.1158/1535-7163.MCT-16-0342. Epub 2016 Dec 15.


Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.

Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C.

Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2.


An overview of long non-coding RNAs in ovarian cancers.

Meryet-Figuière M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, Denoyelle C.

Oncotarget. 2016 Jul 12;7(28):44719-44734. doi: 10.18632/oncotarget.8089. Review.


Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among farmers involved in open field farming and/or cattle breading in France.

Lecluse Y, Comby E, Mariotte D, Tual S, Le Mauff B, Lebailly P, Gauduchon P.

Leuk Lymphoma. 2016 Jul;57(7):1727-30. doi: 10.3109/10428194.2015.1113277. Epub 2015 Dec 21. No abstract available.


Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.

Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L, N'Diaye M.

Apoptosis. 2015 Apr;20(4):535-50. doi: 10.1007/s10495-015-1095-3.


miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.

Denoyelle C, Lambert B, Meryet-Figuière M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, Juin P, Poulain L.

Cell Death Dis. 2014 Oct 9;5:e1445. doi: 10.1038/cddis.2014.389.


PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.

Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18.


Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.

Tomasina J, Poulain L, Abeilard E, Giffard F, Brotin E, Carduner L, Carreiras F, Gauduchon P, Rault S, Malzert-Fréon A.

Int J Pharm. 2013 Dec 15;458(1):197-207. doi: 10.1016/j.ijpharm.2013.09.025. Epub 2013 Sep 29.


Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.

Tomasina J, Malzert-Freon A, Giffard F, Brotin E, Louis MH, Abeilard E, Rault S, Gauduchon P, Poulain L.

J Ovarian Res. 2013 Jun 5;6(1):38. doi: 10.1186/1757-2215-6-38.


Nanocarriers for the targeted treatment of ovarian cancers.

Tomasina J, Lheureux S, Gauduchon P, Rault S, Malzert-Fréon A.

Biomaterials. 2013 Jan;34(4):1073-101. doi: 10.1016/j.biomaterials.2012.10.055. Epub 2012 Nov 20. Review.


Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance.

Lincet H, Guével B, Pineau C, Allouche S, Lemoisson E, Poulain L, Gauduchon P.

J Proteomics. 2012 Feb 2;75(4):1157-69. doi: 10.1016/j.jprot.2011.10.030. Epub 2011 Nov 12.


Influence of the introduction of a solubility enhancer on the formulation of lipidic nanoparticles with improved drug loading rates.

Malzert-Fréon A, Saint-Lorant G, Hennequin D, Gauduchon P, Poulain L, Rault S.

Eur J Pharm Biopharm. 2010 Jun;75(2):117-27. doi: 10.1016/j.ejpb.2010.02.003. Epub 2010 Feb 6.


Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.

Varin E, Denoyelle C, Brotin E, Meryet-Figuière M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L.

Carcinogenesis. 2010 Jun;31(6):984-93. doi: 10.1093/carcin/bgq026. Epub 2010 Feb 8.


Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma.

Labiche A, Heutte N, Herlin P, Chasle J, Gauduchon P, Elie N.

Int J Gynecol Cancer. 2010 Jan;20(1):28-33. doi: 10.1111/IGC.0b013e3181bda1cb.


ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.

Chantepie SP, Vaur D, Grunau C, Salaün V, Briand M, Parienti JJ, Heutte N, Cheze S, Roussel M, Gauduchon P, Leporrier M, Krieger S.

Leuk Res. 2010 Jun;34(6):800-8. doi: 10.1016/j.leukres.2009.10.018. Epub 2009 Nov 26.


Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, Denoyelle C, Gauduchon P, Poulain L.

Mol Cancer Ther. 2009 Nov;8(11):3162-70. doi: 10.1158/1535-7163.MCT-09-0493. Epub 2009 Nov 3.


Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.

Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L.

Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787.


Agricultural pesticide exposure and the molecular connection to lymphomagenesis.

Agopian J, Navarro JM, Gac AC, Lecluse Y, Briand M, Grenot P, Gauduchon P, Ruminy P, Lebailly P, Nadel B, Roulland S.

J Exp Med. 2009 Jul 6;206(7):1473-83. doi: 10.1084/jem.20082842. Epub 2009 Jun 8.


t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals.

Lecluse Y, Lebailly P, Roulland S, Gac AC, Nadel B, Gauduchon P.

Leukemia. 2009 Jun;23(6):1190-3. doi: 10.1038/leu.2009.31. Epub 2009 Feb 26. No abstract available.


Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma.

Labiche A, Elie N, Herlin P, Denoux Y, Crouet H, Heutte N, Joly F, Héron JF, Gauduchon P, Henry-Amar M.

Histol Histopathol. 2009 Apr;24(4):425-35. doi: 10.14670/HH-24.425.


Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease.

Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A, Ngo-Van Do A, Nataf V, Batalla A, Gauduchon P, Talbot JN, Montravers F.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):396-405. doi: 10.1007/s00259-008-0984-x. Epub 2008 Dec 3.


[Epithelial ovarian tumor microecology].

Leroy-Dudal J, Kellouche S, Gauduchon P, Carreiras F.

Bull Cancer. 2008 Sep;95(9):829-39. doi: 10.1684/bdc.2008.0674. Review. French.


Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG.

Aide N, Labiche A, Herlin P, Paciencia M, Poulain L, Dutoit S, Montravers F, Gauduchon P, Chasle J.

Mol Imaging Biol. 2008 Sep;10(5):237-44. doi: 10.1007/s11307-008-0144-5. Epub 2008 Jun 10.


A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.

Le Moguen K, Lincet H, Marcelo P, Lemoisson E, Heutte N, Duval M, Poulain L, Vinh J, Gauduchon P, Baudin B.

Proteomics. 2007 Nov;7(22):4090-101.


Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat study.

Aide N, Louis MH, Dutoit S, Labiche A, Lemoisson E, Briand M, Nataf V, Poulain L, Gauduchon P, Talbot JN, Montravers F.

Nucl Med Commun. 2007 Oct;28(10):813-22.


Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.

Neuro Oncol. 2007 Oct;9(4):412-23. Epub 2007 Jul 10.


Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.

Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 May;105(2):373-84. Epub 2007 Feb 5.


Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.

Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 Apr;105(1):31-44. Epub 2007 Feb 1.


Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.

Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P.

Anticancer Res. 2006 Sep-Oct;26(5A):3561-6.


Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1.

Maubant S, Leroy-Dudal J, Carreiras F, Deslandes E, Duigou F, Staedel C, Gauduchon P.

Cell Biol Int. 2007 Feb;31(2):109-18. Epub 2006 Sep 23.


Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.

Roulland S, Navarro JM, Grenot P, Milili M, Agopian J, Montpellier B, Gauduchon P, Lebailly P, Schiff C, Nadel B.

J Exp Med. 2006 Oct 30;203(11):2425-31. Epub 2006 Oct 16. Erratum in: J Exp Med. 2006 Oct 30;203(11):2563.


Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.

Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P, Baudin B.

Proteomics. 2006 Oct;6(19):5183-92.


Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals.

Roulland S, Lebailly P, Lecluse Y, Heutte N, Nadel B, Gauduchon P.

Leukemia. 2006 Jan;20(1):158-62. No abstract available.


Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice.

Louis MH, Dutoit S, Denoux Y, Erbacher P, Deslandes E, Behr JP, Gauduchon P, Poulain L.

Cancer Gene Ther. 2006 Apr;13(4):367-74.


Seasonal variations of DNA-adduct patterns in open field farmers handling pesticides.

Le Goff J, André V, Lebailly P, Pottier D, Périn F, Périn O, Gauduchon P.

Mutat Res. 2005 Nov 10;587(1-2):90-102. Epub 2005 Sep 2.


Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents.

Loyant V, Jaffré A, Breton J, Baldi I, Vital A, Chapon F, Dutoit S, Lecluse Y, Loiseau H, Lebailly P, Gauduchon P.

Mutagenesis. 2005 Sep;20(5):365-73. Epub 2005 Aug 16.


Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens.

Maubant S, Cruet-Hennequart S, Dutoit S, Denoux Y, Crouet H, Henry-Amar M, Gauduchon P.

J Mol Histol. 2005 Feb;36(1-2):119-29.


[Study of in vitro cytotoxic activity of cyclopentanones derivatives].

Ben Sassi A, Tabka T, Gauduchon P, Dallemagne P, Aouni M.

Tunis Med. 2004 Oct;82(10):919-26. French.


Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2.

Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R, Gauduchon P, Carreiras F.

Int J Cancer. 2005 Apr 20;114(4):531-43.


GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma.

Abbas A, Delvinquiere K, Lechevrel M, Lebailly P, Gauduchon P, Launoy G, Sichel F.

World J Gastroenterol. 2004 Dec 1;10(23):3389-93.


Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides.

Roulland S, Lebailly P, Lecluse Y, Briand M, Pottier D, Gauduchon P.

Cancer Res. 2004 Mar 15;64(6):2264-9.


Urine mutagenicity and lymphocyte DNA damage in fruit growers occupationally exposed to the fungicide captan.

Lebailly P, Devaux A, Pottier D, De Meo M, Andre V, Baldi I, Severin F, Bernaud J, Durand B, Henry-Amar M, Gauduchon P.

Occup Environ Med. 2003 Dec;60(12):910-7.


Correspondence re: Welzel et al, Cancer Res, 61: 1629-1636.

Roulland S, Lebailly P, Gauduchon P.

Cancer Res. 2003 Apr 1;63(7):1722-3. No abstract available.


alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells.

Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S.

Oncogene. 2003 Mar 20;22(11):1688-702.


BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: lack of seasonal variations in frequency and molecular features.

Roulland S, Lebailly P, Roussel G, Briand M, Cappellen D, Pottier D, Hardouin A, Troussard X, Bastard C, Henry-Amar M, Gauduchon P.

Int J Cancer. 2003 May 10;104(6):695-8.


Urine mutagenicity of farmers occupationally exposed during a 1-day use of chlorothalonil and insecticides.

André V, Lebailly P, Pottier D, Deslandes E, De Méo M, Henry-Amar M, Gauduchon P.

Int Arch Occup Environ Health. 2003 Feb;76(1):55-62. Epub 2002 Oct 2.


[Integrins, cell response to anti-tumor agents and chemoresistance].

Maubant S, Staedel C, Gauduchon P.

Bull Cancer. 2002 Nov;89(11):923-34. Review. French.

Supplemental Content

Loading ...
Support Center